<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079624</url>
  </required_header>
  <id_info>
    <org_study_id>GIP/GLP-gastric empt-APP-hor</org_study_id>
    <secondary_id>K2010-55X -07916-24-3</secondary_id>
    <nct_id>NCT01079624</nct_id>
  </id_info>
  <brief_title>GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose</brief_title>
  <acronym>GIP-GLP-gas</acronym>
  <official_title>Effects of GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose Homeostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Academic phase 1 study which investigates the effects of the two incretin hormones
      glucose-insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) on gastric emptying,
      appetite, insulin release and glucose disposal in the body. The hypothesis is that incretin
      hormones not only stimulate insulin release but also inhibits gastric emptying. This effect
      can be utilized for further drug development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effects of GIP and GLP-1 on gastric emptying, appetite control and insulin release in
      relation to glucose levels in the bloodstream. Infusions of GIP and GLP-1 are given under
      simultaneous gastric emptying study and appetite questionnaires and blood sampling for
      analysis of insulin, glucose, and other gut hormones such as glucagon, ghrelin, and PYY, as
      well as those administered, GIP and GLP-1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric emptying rate</measure>
    <time_frame>2005-2006</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose, insulin release, appetite</measure>
    <time_frame>2005-2006</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Physiology</condition>
  <condition>Gastroenterology</condition>
  <condition>Endocrinology</condition>
  <arm_group>
    <arm_group_label>GIP two doses and GLP-1 one dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with infusion of GIP or GLP-1 intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose-insulinotropic peptide, Glucagon-like peptide-1</intervention_name>
    <description>GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min</description>
    <arm_group_label>GIP two doses and GLP-1 one dose</arm_group_label>
    <arm_group_label>Saline infusion</arm_group_label>
    <other_name>GIP</other_name>
    <other_name>GLP-1</other_name>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women

          -  18-50 years old;

          -  otherwise healthy and HIV and HCB, HCV negative

        Exclusion Criteria:

          -  Age &gt;50,

          -  all types of diseases and drug users.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per M Hellstrom, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet, Uppsala University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <last_update_submitted>March 2, 2010</last_update_submitted>
  <last_update_submitted_qc>March 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professor Per Hellstr√∂m</name_title>
    <organization>Uppsala University</organization>
  </responsible_party>
  <keyword>Incretin hormones</keyword>
  <keyword>Glucose-insulinotropic peptide</keyword>
  <keyword>Glucagon-like peptide-1</keyword>
  <keyword>Gastric emptying</keyword>
  <keyword>Appetite</keyword>
  <keyword>Glucose disposal</keyword>
  <keyword>Gut hormones</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

